It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good day everyone and welcome to today’s Avadel Pharmaceuticals ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

Joseph Thome, an analyst from TD Cowen, maintained the Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report). The associated price ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

The Pharma & Biotech market had a relatively muted month. There were a number of companies that experienced strong share ...

Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Third Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session will ...

Rigel Pharmaceuticals, Inc. beats earnings expectations ... expanding our commercial portfolio and increasing product sales.

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

Prabhudas Lilladher is bullish on Apollo Hospitals Enterprise has recommended buy rating on the stock with a target price of ...